Pacira BioSciences Inc [PCRX] stock prices are up 0.50% to $24.19 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PCRX shares have gain 4.40% over the last week, with a monthly amount glided 9.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist upgraded its rating to Buy on July 25, 2025, and kept the price target unchanged to $30. On January 30, 2025, upgrade upgraded it’s rating to Hold and revised its price target to $25 on the stock. Truist downgraded its rating to a Sell and decreased its price target to $8 on August 13, 2024. RBC Capital Mkts downgraded its rating to a Sector Perform and reduced its price target to $14 on August 12, 2024. Raymond James downgraded its rating to Mkt Perform for this stock on August 12, 2024. In a note dated August 12, 2024, Piper Sandler downgraded an Neutral rating on this stock and revised its target price from $42 to $11.
The stock price of Pacira BioSciences Inc [PCRX] has been fluctuating between $16.41 and $27.64 over the past year. Currently, Wall Street analysts expect the stock to reach $34.57 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $24.19 at the most recent close of the market. An investor can expect a potential return of 42.91% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
The Pacira BioSciences Inc [NASDAQ:PCRX] reported sales of 716.79M for trailing twelve months, representing a surge of 6.49%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.04 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.77 points at the first support level, and at 23.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.71, and for the 2nd resistance point, it is at 25.23.
Ratios To Look Out For
It’s worth pointing out that Pacira BioSciences Inc [NASDAQ:PCRX]’s Current Ratio is 5.26. Also, the Quick Ratio is 3.78, while the Cash Ratio stands at 1.38. Considering the valuation of this stock, the price to sales ratio is 1.45, the price to book ratio is 1.43 and price to earnings (TTM) ratio is 54.23.
Transactions by insiders
Recent insider trading involved SLONIN JONATHAN, Chief Medical Officer, that happened on Nov 17 ’25 when 3960.0 shares were sold. Officer, SLONIN JONATHAN completed a deal on Nov 17 ’25 to buy 3960.0 shares. Meanwhile, Chief Financial Officer Cross Shawn sold 12060.0 shares on Nov 10 ’25.
